NYSE: PTN)" src="https://www.abnewswire.com/upload/2025/03/1743208015.jpg" alt="Palatin Technologies' UC Treatment Shows Remarkable 78% Clinical Response Rate in Phase 2 Topline Data - Potential Game-Changer for Millions Suffering from Ulcerative Colitis (NYSE: PTN)" width="225" height="225">

Palatin Technologies (NYSE American: PTN)* just unveiled remarkable topline results from its Phase 2 study of PL8177 for ulcerative colitis (UC), demonstrating what could be a disruptive new treatment approach for this debilitating inflammatory bowel condition.

The data seems impressive - an extraordinary 78% of patients treated with PL8177 achieved clinical response compared to just 33% for placebo, with statistical significance (p<0.005). Even more encouraging, 33% of treated patients reached full clinical remission while none of the placebo patients did. The treatment also demonstrated a perfect safety record with zero adverse events reported, a crucial advantage in a therapeutic area plagued by treatments with serious side effects.

"We are thrilled with the positive results in this study, especially the meaningful and high rates of achievement for clinical remission and clinical response," stated Carl Spana, Ph.D., President and CEO of Palatin, in the company's announcement. "Most patients showed significant symptom and endoscopic score improvements after just eight weeks of treatment."

Palatin's approach with PL8177, which targets the melanocortin-1 receptor (MC1R), represents a completely novel mechanism in the UC treatment landscape. This once-daily oral medication could revolutionize care for the approximately 1.25 million Americans suffering from UC, particularly the 350,000+ diagnosed with moderate-to-severe disease who currently face limited and often problematic treatment options.

The results were especially striking in patients with more extensive disease. Among those with inflammation in all three colon segments, 60% of PL8177-treated patients showed improvement across all segments, and a remarkable 80% improved in at least two segments. Not a single placebo patient showed comparable improvement.

"Seeing a good percentage of patients treated with PL8177 achieve strong results for clinical remission and clinical response in this short study on UC patients is a compelling indicator that melanocortin-1 receptor agonists could be a promising treatment option for UC," noted Dr. Dana J. Lukin, Clinical Director of the Jill Roberts Center for Inflammatory Bowel Disease at Weill Cornell Medicine-New York Presbyterian Hospital, in Palatin's release.

This breakthrough comes just days after Palatin received FDA orphan drug designation for another compound, PL7737, targeting obesity caused by leptin receptor deficiency. The company appears to be hitting its stride with its melanocortin receptor technology platform, which also shows promise in dry eye disease and diabetic nephropathy.

Perhaps most exciting for those following the company, Dr. Spana revealed that "several major pharmaceutical companies have shown strong interest in our UC program," suggesting that partnership or licensing deals might be imminent. For a small biotech with multiple promising programs, such deals could be transformative.

With Palatin also set to release results from its eagerly anticipated Phase 2 BMT-801 obesity study combining bremelanotide with tirzepatide any day now, the company is quickly emerging as one of biotech's most compelling stories of 2025.

Recent Palatin Technologies News Highlights:

• Completion of Phase 2 Obesity Study With MC4R Bremelanotide Plus GLP-1/GIP Tirzepatide
• Palatin Announces Positive Phase IIb BREAKOUT Study Results in Patients with Type 2 Diabetic Nephropathy
• Palatin Announces Completion of Patient Enrollment in Phase 2 Study of Orally Administered Melanocortin Agonist PL8177 in Ulcerative Colitis

*DISCLAIMER: This alert is published by Wall Street Wire. Wall Street Wire does not provide financial or investment advice, and our content does not represent an offer to buy or sell securities. Wall Street Wire is a promotional content brand and its operators are not registered brokers, dealers, or investment advisers. This alert contains and is a form of paid promotional content for to Palatin Technologies and was produced as part of their paid subscription to Wall Street Wire’s distribution and promotional content services. This alert has not been reviewed or approved by Palatin Technologies prior to publication. Please review the full disclaimers and compensation disclosures here: redditwire.com/terms

Media Contact
Company Name: Wall Street Wire
Contact Person: Editorial Staff
Email: Send Email
Country: United States
Website: https://newsletter.page/wallstreetalerts